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INTRODUCTION
Chemotherapy- or growth factor–mobilized peripheral
blood stem cells (G-PBSC) have become the standard of
care for autologous treatment of therapy-induced cytopenia.
The ability to collect large numbers of stem cells with little
duress to patients combined with accelerated engraftment
kinetics suggests that the use of stem cell rescue will
increase in the future. Mobilization of hematopoietic stem
cells (HSCs) also mobilizes tumor cells, which may con-
tribute to relapse [1–3]. To address this issue, investigators
have used positive selection of CD34 cells with and with-
out negative selection to reduce the tumor burden [4–13].
Alternatively, pharmacological agents have been used for
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ABSTRACT
The application of ex vivo expansion to cell products pharmacologically purged in vitro may provide sufficient num-
bers of cells for rapid engraftment in a product with reduced tumor burden. To pursue this possibility we evaluated
the effect of 4-hydroperoxycyclophosphamide (4-HC) treatment on granulocyte colony-stimulating factor–mobi-
lized peripheral blood stem cells (G-PBSC) and their subsequent expansion potential. A small number of G-PBSC
CD34 cells are resistant to 4-HC and are phenotypically and functionally immature. 4-HC–resistant G-PBSC cells
are CD34 bright, CD38/, DRlo, CD13lo, CD33, CD71, and rhodamine dull. In six experiments, treating G-
PBSC with 60 g/mL of 4-HC at 37C for 30 minutes reduced the number of colony-forming units (CFUs) per
5000 CD34 cells by 96.3% (from 1333  137 to 46.5  11). This purging also reduced the frequency of 5-week
long-term culture initiating cells (LTC-ICs) from 1/39 (range 1/27 to 1/62) to 1/1680 (range 1/1180 to 1/2420).
Ex vivo expansion cultures were used to compare the proliferative potential of treated and untreated CD34 cells.
These cells were cultured with either the HS-5 stromal cell line serum-deprived conditioned media supplemented
with 10 ng/mL kit ligand (HS-5CM/KL) or a recombinant growth factor mix (GFmix) containing 10 ng/mL each of
interleukin (IL)-1, IL-3, IL-6, KL, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulat-
ing factor, and 3 U/mL of erythropoietin. Culturing untreated CD34 G-PBSC with 10% HS-5CM/KL increased
total nucleated cells by 460-fold after 15 days. Progenitors, which were measured as CFUs, also increased by 47-
fold over the same period. More significantly, culturing the 4-HC–treated CD34 cells with HS-5/KL increased
CFUs 98-fold and the nucleated cells increased 4573-fold. The absolute number of CFUs present after expansion of
the 4-HC–resistant cells with HS-5CM/KL was threefold higher than that detected before purging and significantly
higher than that obtained with GFmix. These data indicate that G-PBSC contain a very immature pool of cells not
detectable using the 5-week LTC-IC assay, but have extremely high proliferative potential. Additionally, pharmaco-
logical purging of G-PBSC greatly reduces mature cells while retaining an immature population. Also significant is
the finding that supernatant from the HS-5 bone marrow stromal cell line plus KL can fully regenerate progenitors
from the 4-HC–resistant CD34 G-PBSC.
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purging both bone marrow (BM) and peripheral blood auto-
grafts [14–24].
Extensive reduction in progenitor cells after purging BM
products with 4-hydroperoxycyclophosphamide (4-HC) cor-
relates with the extended duration of cytopenia after trans-
plantation [25]. In theory, this delay in hematopoietic recov-
ery may be reduced by the infusion of large numbers of pro-
genitors, which could be generated ex vivo. For the expansion
of 4-HC–purged CD3433 cells, it was initially demon-
strated that stroma was an absolute requirement [26]. Subse-
quently, it was shown that culturing purged cells with a mini-
mum of ﬁve recombinant cytokines could also increase the
number of nucleated cells. However, to what extent pro-
genitor cells were regenerated was not established.
Pharmacological purging can also be used to evaluate
the maturation status of hematopoietic cell products.
Numerous investigators have compared G-PBSC, enriched
CD34 populations, and subpopulations of CD34 cells
such as DRlo or CD38lo with analogous populations in BM
or steady-state peripheral blood [27–35]. G-PBSC CD34
cells are phenotypically comparable with those detected in
steady-state PBSC, but they differ from those in BM. Fewer
BM CD34 cells express CD13 and CD33 and a greater
number of marrow cells are CD19 and CD20. Although
the G-PBSC product phenotypically appears to contain
more cells that are committed to the myeloid lineage than
do BM products, functional analysis reveals that a compa-
rable percentage of CD34 cells are colony forming units
(CFUs) and long-term culture initiating cells (LTC-ICs).
Further, relative to the numbers present in steady-state
peripheral blood, the mobilized product contains greater
numbers of LTC-ICs. Note that the immature
CD34DR/38 subpopulations in both steady state and G-
PBSC contain comparable frequencies of LTC-ICs
(0.5–2.0%). However, in G-PBSC the majority of LTC-ICs
are within the more mature CD34DR/38 populations
[35]. A large percentage (90–95%) of the DR and 38
LTC-ICs are of intermediate maturity and only provide
CFUs for up to 5 weeks in culture [35]. 
By a thorough analysis of the phenotype and the matu-
ration status of 4-HC–resistant cells, we here assess the
effects of 4-HC purging on G-PBSC. We demonstrate that
committed progenitors, measured as CFUs and 5-week
LTC-ICs, are highly sensitive to 4-HC. Further, we
demonstrate that the immature 4-HC–resistant cells can




Normal G-PBSC was obtained by informed consent in
accordance with the Fred Hutchinson Cancer Research
Center Institutional Review Board guidelines. Red blood
cells were removed from apheresis products by hemolysis
with 150 mM NH4CL2 at 37°C. Nucleated cells were stored
frozen in RPMI, 36% fetal bovine serum (FBS), 10%
dimethyl sulfoxide (DMSO), 90 U of penicillin, 90 g/mL
of streptomycin sulfate, and 0.36 g/mL of glutamine. The
stored cells were thawed quickly at 37°C and diluted at
room temperature with medium-199 plus heparin to a ﬁnal
DMSO concentration below 1%. After an overnight incuba-
tion at 4°C, the cells were washed and then treated with 4-
HC as described below. 
4-HC treatment
G-PBSC was treated according to previously published
guidelines for purging BM [36]. Before isolating CD34
cells, the thawed G-PBSC product was divided into two
aliquots of 2107 cells/mL in RPMI plus 20% FBS. The
treated sample received 4-HC (Scios Nova, Mountain View,
CA) at a ﬁnal concentration of 60 g/mL, and both aliquots
were incubated at 37°C for 30 minutes. After incubation, the
CD34 cells were washed 3 times in 10 vol RPMI/20% FBS
to remove residual 4-HC, pelleted, and then resuspended in
phosphate-buffered saline (PBS)/1% bovine serum albumin
(BSA) to stain before sorting.
Isolation of CD34 cells
Treated and untreated cells were labeled with anti-CD34
antibody (HPCA-2 [IgG1], Becton Dickinson, San Jose, CA)
conjugated to ﬂuorescein isothiocyanate (FITC) for 20 min-
utes on ice, then washed with PBS containing 1% BSA. Cells
with medium to high forward light scatter and low side scat-
ter were selected, and CD34 cells were enriched to 60–70%
purity using the enrichment mode of a FACStar plus (Becton
Dickinson). For purity 98%, the enriched cells were again
sorted using the normal-R mode. 
Conditioned medium
HS-5 cells were plated at 2106 cells per 75 cm2 in
RPMI containing 5% FBS. After 24 hours, the serum con-
taining medium was removed and the cultures washed 2
times with Hanks’ balanced salt solution (HBSS). The cells
were then fed with serum-deprived medium composed of
Iscove’s modiﬁed Dulbeccos medium (IMDM), 1% nutrido-
ma-HU, 2 mmol/L of L-glutamine, 1 mmol/L of sodium
pyruvate, 50 U/mL of penicillin, and 50 g/mL of strepto-
mycin sulfate. Supernatants were harvested after 7 days and
culture debris was pelleted by centrifugation at 2000g for 10
minutes. Conditioned medium was stored at 4C, and batch-
es were tested for colony formation activity before concen-
trated as previously described [36]. Conditioned medium was
concentrated ﬁvefold by a reduction in volume using Cen-
triprep 10 concentrators (Amicon, Beverly, MA) with a 10 kd
cutoff, according to manufacturer specifications, and is
referred to as HS-5 conditioned medium (HS-5CM).
Ex vivo expansion
Expansion cultures were initiated with 1104 cells/mL in
serum-deprived medium (described above) that was supple-
mented with either 10% HS-5CM/kit ligand (HS-5CM/KL)
or GFmix containing 10 ng/mL each of interleukin (IL)-1,
IL-3, IL-6, granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage (GM)-CSF, KL, and 3 U/mL of
erythropoietin (Epo). The initial expansions were performed
in the absence of FBS, but the expansion of 4-HC–treated
cells required the addition of FBS to a ﬁnal concentration of
10%. Cultures were incubated at 37C in 5% CO2 for differ-
ent time periods and fed at the start of the expansion. For
each time point, triplicate wells were analyzed for total viable
cell number, CFU content, or LTC-ICs. 
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Phenotypic analysis
After sorting the treated and untreated cells, the
enriched CD34 products were placed into expansion cul-
tures. The cells were incubated in expansion medium for 48
hours, which provided sufﬁcient time for the 4-HC to kill
sensitive cells. After this incubation, the anti-CD34 anti-
body was no longer present and thus restaining of cells was
required for phenotypic analysis. The cells were then har-
vested and labeled with either anti-CD34 (HPCA-2, IgG1),
anti-CD38 (Leu-17, IgG1), anti–HLA-DR (MHC II,
IgG2a), anti-CD13 (Leu-M7, IgG1), anti-CD33 (Leu-M9,
IgG1), anti-CD71 (anti-transferrin receptor, IgG2a), and the
following isotype controls: mouse IgG1-PE, mouse IgG2a-
PE, mouse IgG2a-F from Becton Dickinson. The cells were
incubated for 20 minutes on ice with the appropriate anti-
body and then washed with PBS containing 1% BSA.
Labeled cells were then analyzed using a FACScan (Becton
Dickinson) and data was collected in list mode. 
Rhodamine staining
Staining with Rho123 was performed as previously
described [37]. Brieﬂy, cells were incubated at 37°C for 45
minutes with 0.1 g/mL of Rho123. The cells were then
washed twice with HBSS and incubated again at 37°C for 15
minutes in HBSS to eliminate excess dye. Cells were washed
again and then used for ﬂow cytometry. Staining was stable
for at least 3 hours when protected from light. 
7-Amino-actinomycin D staining
Before flow cytometric analysis, 15 L of 7-amino-
actinomycin D ([7-AAD] 50 ng/L) was added to 1.0 mL
of cell suspension. The cells were incubated for a mini-
mum of 15 minutes on ice before analysis. 
Colony assays
Colony assays were established and scored as previously
described [36]. Briefly, cells were cultured in semisolid
medium containing 1.2% methylcellulose, 2.5% BSA, 25%
FBS (Hyclone, Logan, UT), 100 U of penicillin, 100
g/mL of streptomycin sulfate, and 0.1 M of 	-mercap-
toethanol. Colony-stimulating activity was provided by 10%
HS-5CM/KL and 3 U/mL of Epo. Hematopoietic cells plus
conditioned medium was added to 0.9 mL of the methylcel-
lulose stock. Colony formation was scored at day 14. 
LTC-IC limiting dilution analysis
Two- to four-week-old primary LTCs established and
maintained according to previously published guidelines
[38,39] were irradiated at 2000 cGy with 137Cs, and 25,000
cells were plated into the middle of each of 60 wells of a
96-well plate at least 24 hours before the addition of
hematopoietic cells. The stromal cultures were seeded with
untreated CD34 cells at 5, 10, 25, 50, 75, and 100 cells
per well (20 wells each) using single-cell deposition on a
Becton Dickinson FACStar Plus before expansion, and
after demidepletion were fed weekly for 5 weeks. For the
first three experiments, the 4-HC–treated CD34 cells
were plated at the same cell densities as those of the
untreated cells; for the next three experiments, 25, 50, 100,
200, 400, and 800 cells per well were plated. The CD34
cells, with and without 4-HC treatment, were expanded
for 12 days and then plated at various concentrations,
depending on the extent of expansion. LTC-ICs were
detected by removal of the adherent layer and culturing in
90 L of methylcellulose mix plus 10 L of recombinant
GFmix for 2 weeks, at the end of which time colonies were
scored. Calculations of absolute numbers of LTC-ICs were
derived from their frequency within the expanded popula-
tion, based on the proportion of negative wells from the
limiting dilution analysis using Poisson statistics with max-
imum likelihood estimation [40].
RESULTS
Expansion of CD34+ G-PBSC in serum-deprived media
Using serum-free culture conditions previously estab-
lished with BM cells, the CD34 cells from G-PBSC were
cultured and analyzed for total nucleated cells (TNCs) and
CFUs. Figure 1A demonstrates that extensive production
of nucleated cells was possible from G-PBSC CD34 cells
in the absence of serum. A significantly greater production
of cells after 12 and 15 days was obtained with HS-
5CM/KL ( p  0.001 for both time points) compared with
cultures expanded with recombinant growth factors. Maxi-
mum myeloid CFU production was obtained at day 8 with
the recombinant factors, whereas HS-5CM/KL main-
tained production for an additional 4 days, resulting in
significant differences in the number of CFU generated (p
 0.01) (Fig. 1B). 
Immuno-phenotypic analysis
To assess the effect of 4-HC treatment on G-PBSC, we
compared the immuno-phenotype, progenitor, and LTC-IC
content of the 4-HC–treated CD34 cells with untreated
CD34 cells. These two populations were evaluated for via-
bility and phenotypic markers 48 hours after either a pulse
with 4-HC or mock treatment and initiation of the expan-
sions. Most (98–99%) of the treated CD34 cells were posi-
tive when stained with 7-AAD (not shown), indicating that
4-HC treatment results in extensive cell death. Gating on
the 7-AAD negative population revealed that 48 hours after
4-HC treatment the resistant cells differed markedly from
untreated cells (Fig. 2). The viable 4-HC–treated cells are
CD34 bright, HLA-DR, and CD71low, CD38
, and rho-
damine dull and display low levels of the myeloid markers
CD13 and CD33. This phenotypic analysis suggests that a
very immature population of cells remains viable after 4-HC
purging of peripheral blood CD34 cells. 
Effect of 4-HC treatment on progenitors from normal G-PBSC
Quadruplicate primary colony assays were performed on
2000 4-HC-treated and 200 untreated CD34 cells from
normal donors (n5). 4-HC treatment signiﬁcantly reduces
the CFU content of the G-PBSC CD34 cells, from 1333

 137 to 46.5 
 11 per 5000 CD34 cells (p  0.001). This
level of reduction was also observed with 4-HC–treated BM
(data not shown) and is consistent with previously published
results using BM [26].
Effect of 4-HC treatment on LTC-ICs from G-PBSC CD34+ cells
Before expansion, CD34 cells were sorted onto pre-
formed irradiated stroma and LTC-IC analysis was per-
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formed. Combining the results from six experiments
revealed a mean frequency of LTC-ICs in untreated G-
PBSC of 1/35.8 
 2.6 (Table 1). In contrast, the LTC-IC
frequency was approximately 1/1666 
 364 for 4-HC–treat-
ed CD34 cells. This reduction was greater than initially
anticipated, preventing detection of this population when a
narrow range of cell concentrations was used in the first
three experiments. Overall, these data indicate that approxi-
mately 96% of the G-PBSC LTC-ICs are sensitive to 4-
HC. After 12 days of expansion, the frequency of LTC-ICs
in the 4-HC–treated group was too low to detect, suggest-
ing that the extensive expansion of TNCs and CFUs deplet-
ed this immature population.
Expansion of G-PBSC
In contrast to results obtained with untreated CD34
cells, no expansion of 4-HC–treated cells was obtained in
the absence of FBS, regardless of whether recombinant
cytokines or HS-5CM was added (data not shown). There-
fore, parallel expansions of treated and untreated CD34
cells were performed with the addition of 10% FBS. In cul-
tures with untreated cells, the expansion was rapid through
the first 8–12 days of culture (Fig. 3). Adding 10% FBS
increased production of nucleated cells fivefold with the
GFmix and 2.5-fold with HS-5CM/KL (compare Fig. 1A
and Fig. 3). 4-HC–resistant cells constituted only 1–2% of
the CD34 cell population; hence, 4-HC-treated cultures
that were initiated with 5000 CD34 cells contained only
50–100 viable cells. For this reason there was an insufﬁcient
number of cells to obtain an accurate cell count until day 8
of culture (Fig. 3, treated arms). The 4-HC–treated cells
continued to expand to day 15 with the GFmix and to day
21 with HS-5CM/KL. 
Production of progenitors from 4-HC–treated cells
Progenitor production from both treated and untreated
CD34 cells is reported in Figure 4. HS-5CM/KL generat-
ed signiﬁcantly more CFUs than did the GFmix (p  0.01)
after 12 days of culture with untreated cells and after 15 days
with treated cells (p  0.01). Moreover, under these expan-
sion conditions, only HS-5CM/KL was able to regenerate 2
times more than the initial number of CFUs before 4-HC
treatment. In contrast, the GFmix cultures regenerated only
58% of the initial number of CFUs. For both treated and
untreated arms, the GFmix had slightly faster production of
progenitors through the ﬁrst 8 days. At this time, the GFmix
progenitor production decreased, whereas HS-5CM/KL
cultures continued to produce progenitors. 
Proliferative index of TNCs and CFUs
By tabulating the mean fold expansion (proliferative
index) of 4-HC–treated and untreated cells for the genera-
tion of nucleated cells and CFUs, it became apparent that
HS-5CM/KL has its greatest effect, in comparison with the
GFmix, on the generation of CFUs from the 4-HC–resistant
population (Table 2). The CFU production stimulated by
HS-5CM/KL from 4-HC-treated cells was 5.16-fold higher
than that by the GFmix. In contrast, TNC production was
similar under either of the two conditions. Expansions initi-
ated with untreated CD34 G-PBSC cells generated num-
bers of TNCs and CFUs approximately 2 times higher with
the HS-5CM/KL combination compared with the GFmix.
DISCUSSION
Our data indicated that a small percentage of normal
G-PBSC CD34 cells are resistant to 4-HC. Phenotypic
Figure 1. Analysis of total nucleated cell (TNC) production (A) and colony-forming unit (CFU) production (B) from G-PBSC CD34 cells
expanded in serum-free conditions with GFmix or HS-5CM/KL
Cultures were fed at the inception of expansion and at each time point the expansion product was assayed in triplicate for TNCs and quadruplicate for CFUs. The
absolute number of TNCs or CFUs are plotted using a logarithmic scale, and each data point represents the mean and standard error of the mean for ﬁve separate
experiments. , production with HS-5CM/KL; , production with GFmix. 
A B
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analysis of the 4-HC–resistant population suggested that
these cells were immature, a factor consistent with their
extensive proliferation upon stimulation with cytokines. We
confirmed that the frequency of 5-week LTC-ICs in
CD34 G-PBSC (1/39) was comparable with that of
CD34 cells from BM (1/40). The G-PBSC–derived LTC-
ICs were extremely sensitive to 4-HC treatment as were
the myeloid progenitor cells measured as CFUs. These data
were consistent with previous observations that G-PBSC
CD34 cells contain a large number of LTC-ICs that may
be of an intermediate maturity status [35]. It was observed
that a large percentage of 5-week LTC-ICs were in the
more CD38 or DR subpopulations of G-PBSC CD34
cells [35]. Hence, the observed reduction of 5-week LTC-
ICs was further substantiated by lower levels of HLA-DR
expression on the resistant population. In contrast, the lack
of CD38 expression did not correlate with maturation sta-
tus, or at least with 4-HC resistance in this study. This fac-
tor was consistent with the inability to separate committed
progenitors in peripheral blood CD34 cells from less
mature LTC-ICs using this marker [41]. 
Previous work established that cultures initiated with
immature CD3438 marrow cells produced large numbers
Figure 2. Phenotypic analysis of CD34 cells from G-PBSC pre– and post–4-HC treatment
Data were collected in list mode and dot plots were generated on pre-gated viable cells as determined by negative staining with 7-AAD. Relevant isotype control
IgG1-PE and IgG1-FITC were used to detect nonspeciﬁc staining. Data are represented as relative ﬂuorescence intensity on the x-axis and relative number on the y-
axis. ( ) phenotype of 4-HC–treated cells; ( ) untreated cells; ( ) isotype control.
Table 1. LTC-IC content in CD34 cells from G-PBSC pre– and post–
4-HC treatment
Pre–4-HC treatment Post–4-HC treatment
Absolute Absolute Percent
Experiment Frequencya numberb Frequencya numberb reduction
1 1/27 185 ND ND ND
2 1/34 143 ND ND ND
3 1/43 116 ND ND ND
4 1/32 156 1/1428 3.5 97.8
5 1/35 143 1/1190 4.2 97.1
6 1/43 116 1/2380 2.1 98.2
aLTC-IC frequency was determined by limiting dilution analysis.
bAbsolute number of LTC-ICs was calculated by multiplying the frequency
times the total number of cells. 
ND, no LTC-ICs detected after 4-HC treatment using the standard range of
cell concentrations for LTC-IC analysis (see Materials and Methods). 
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of nucleated cells and committed progenitors in serum-free
medium [42]. Hence, the dependence on serum for expansion
of the 4-HC–treated cells was initially surprising. One possi-
ble explanation is that 4-HC damages the immature cells and
the FBS helps to facilitate their repair. Another is that the 4-
HC–resistant cells are less mature than the CD3438 BM
population, and thus require additional support for expansion.
Alternatively, 4-HC–resistant peripheral blood cells may be
equivalent to BM CD3438 cells with respect to maturity,
and hence the serum requirement is associated with unknown
differences between these populations. For example, circulat-
ing CD34 cells are quiescent in contrast, i.e., 30–40% of
their marrow counterparts are in S-phase [43].
The first published report on ex vivo expansion of 4-
HC–treated BM cells indicated that stroma was an absolute
requirement for proliferation [26]. With the availability of
additional cytokines it became apparent that, by combining
a large number of factors, similar results could be obtained
in the absence of stroma. In this study, we demonstrated
that the HS-5 stromal supernatant was superior to a recom-
binant growth factor mix for recovery of committed pro-
genitors. This was consistent with the observation that HS-
5CM/KL consistently generates more progenitors in com-
parison with recombinant factors [42]. It is not clear
whether this activity was associated with a novel factor, an
ideal concentration and combination of cytokines, or an
appropriate glycosylation of known factors. 
Ideally, for clinical application, exclusion of FBS is war-
ranted because of the potential for adventitious viral expo-
sure and the inherent variability of animal products. We
found that incorporating 2% autologous plasma in the
serum-free expansion cultures could increase the number of
myeloid progenitors twofold from untreated normal donor
cells and from untreated patient cells (unpublished observa-
tion, B.A.R.). The use of autologous plasma and the HS-
5CM have received initial FDA approval for a phase I clini-
cal trial of untreated G-PBSC. However, what effect autolo-
gous plasma has on the expansion of 4-HC–resistant cells is
unknown and further investigation into its use and the opti-
mization of ex vivo expansion techniques should be pursued.
Purging of autologous products could be beneﬁcial by
extending remission duration or survival after transplanta-
tion. In vitro pharmacological purging of BM with 4-HC
typically results in delayed hematopoietic recovery [25].
Clinical trials have established that the delay in hemato-
poietic recovery correlates with the extent of reduction in
committed progenitors [25]. To spare normal cells and yet
provide tumor reduction, the cell product was pretreated
with the cytoprotectant amifostine before 4-HC purging
[44]. This product engrafted signiﬁcantly faster than stan-
dard 4-HC–treated cells. However, the effect on relapse or
survival has yet to be determined. An alternative approach
would follow in vitro purging with ex vivo expansion of at
least part of the product. In the work presented here, treated
Figure 3. Nucleated cell production from 4-HC–treated and
untreated cells
Analysis of total nucleated cell (TNC) production from untreated and 4-
HC–treated G-PBSC CD34 cells expanded in 10% fetal bovine serum
(FBS) with GFmix or HS-5CM plus 10 ng/mL KL (HS-5CM/KL). Cul-
tures were fed once at the inception of expansion and each time the expansion
product was assayed in triplicate. The absolute number of TNCs is plotted
using a logarithmic scale, and each data point represents the mean and stan-
dard error of the mean for five separate experiments. Circles represent
untreated cells and squares represent the 4-HC–treated cells. HS-5CM/KL
cultures are indicated by open symbols and GFmix cultures by closed symbols.
Figure 4. Progenitor production from 4-HC–treated and untreated
cells
Analysis of CFU production from untreated and 4-HC–treated G-PBSC
CD34 cells expanded in 10% FBS with GFmix or HS-5CM/KL. Cultures
were fed once at the inception of expansion and each time CFUs were assayed
in quadruplicate. The absolute number of CFUs is plotted using a logarithmic
scale and each data point represents the mean and standard error of the mean
for five separate experiments. ( ) starting number of CFUs in 5000
CD34 cells (99% purity) without 4-HC treatment. Circles represent
untreated cells and squares represent the 4-HC–treated cells. HS-5CM/KL
cultures are indicated by open symbols and GFmix cultures by closed symbols.
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cells were taken from normal healthy donors. The effect of
4-HC purging on the expansion potential of cells from
patients that have a history of cancer and previous chemo-
therapy is unknown. Currently, however, our studies using
cells from normal donors indicate that HS-5CM/KL seems
optimal for this purpose.
ACKNOWLEDGMENTS
The authors thank Gretchen Johnson and Ludmila Gol-
ubev for their technical assistance.
REFERENCES
1 Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N,
Ttallman MS, Kennedy MJ, Davidson NE, Sweet D, Winter C, Akard L,
Jansen J, Copelan E, Meagher RC, Herzig RH, Klumpp TR, Kahn DG,
Warner NE: Detection and viability of tumor cells in peripheral blood
stem cell collections from breast cancer patients using immunocyto-
chemical and clonogenic assay techniques. Blood 82:2605, 1993.
2 Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L:
Mobilization of tumor cells and hematopoietic progenitor cells into
peripheral blood of patients with solid tumors. Blood 83:636, 1994.
3 Shpall EJ, Jones RB: Release of tumor cells from bone marrow.
Blood 83:623, 1994.
4 Berenson RJ, Bensinger WI, Kalamasz D: Positive selection of viable
cell populations using avidin-biotin immunoadsorption. J Immunol
Methods 91:11, 1991. 
5 Berenson RJ, Bensinger WI, Hill R, Andrews R, Garcia-Lopez J, Kala-
masz D, Still B, Spitzer G, Buckner C, Bernstein I, Thomas E: Engraftment
after infusion of CD34 marrow cells in patients with breast cancer or
neuroblastoma. Blood 77:1717, 1991.
6 Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Curiel T,
Bitter M, Claman HN, Stemmer SM, Purdy M, Myers SE, Hami L, Taff S,
Heimfeld S, Hallagan J, Berenson R: Transplantation of enriched CD34-
positive autologous marrow into breast cancer patients following high-
dose chemotherapy: inﬂuence of CD34-positive peripheral-blood pro-
genitors and growth factors on engraftment. J Clin Oncol 12:28, 1994.
7 Fruehauf S, Haas R, Zeller WJ, Hunstein W: CD34 selection for
purging in multiple myeloma and analysis of CD34 B cell precursors.
Stem Cells 12:95, 1994.
8 Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH,
Cao J, Lee JC, Hong CH, Lichtenstein A, Lill M, Hall J, Berenson R, Beren-
son J: Transplantation of CD34 peripheral blood progenitor cells after
high-dose chemotherapy for patients with advanced multiple myeloma.
Blood 86:390, 1995.
9 Nimgaonkar M, Kemp A, Lancia J, Ball ED: A combination of
CD34 selection and complement-mediated immunopurging (anti-
CD15 monoclonal antibody) eliminates tumor cells while sparing nor-
mal progenitor cells. J Hematother 5:39, 1996.
10 Berenson RJ, Shpall EJ, Auditore-Hargreaves K, Heimfeld S, Jacobs C,
Krieger MS: Transplantation of CD34 hematopoietic progenitor cells.
Cancer Invest 14:589, 1996.
11 Paulus U, Dreger P, Viehman K, von Neuhoff N, Schmitz N: Purging
peripheral blood progenitor cell grafts from lymphoma cells: quantita-
tive comparison of immunomagnetic CD34 selection systems. Stem
Cells 15:297, 1997.
12 Paulus U, Schmitz N, Viehman K, von Neuhoff N, Dreger P: Com-
bined positive/negative selection for highly effective purging of PBPC
grafts: towards clinical application in patients with B-CLL. Bone Mar-
row Transplant 20:415, 1997. 
13 Rocca P, Roecklein BA, Mills B, Rowley S: Double-purging consisting
of CD34 cell selection and B-cell depletion versus CD34 selection
alone: pre-clinical study. Blood 90:218a, 1997. [abstr]
14 Kvalheim G, Wang M, Pharo A, Holte H, Jacobsen E, Beiske K, Kvaloy
S, Smeland E, Funderud S, Fodstad O: Purging of tumor cells form leuka-
pheresis products: experimental and clinical aspects. J Hematother
5:427, 1996.
15 Motta MR, Mangianti S, Rizzi S, Ratta M: Pharmacological purging
of minimal residual disease from peripheral blood stem cell collections
of acute myeloblastic leukemia patients: pre-clinical studies. Exp Hema-
tol 25:1261, 1997.
16 Yeager A, Kaizer H, Santos G, Saral R, Colvin M, Stuart R, Braine H,
Burke P, Ambinder R, Burns W, Fuller D, Davis J, Karp J, Stratford W,
Rowley S, Sensenbrenner L, Vogelsang G, Wingard J: Autologous bone
marrow transplantation in patients with acute non-lymphocytic
leukemia, using ex vivo marrow treatment with 4-hydroperoxycy-
clophosphamide. N Engl J Med 315:141, 1986. 
17 Okamoto S, Olson AC, Vogler WR, Winton EF: Purging leukemic
cells from simulated remission marrow with alkyl-lysophospholipid.
Blood 69:1381, 1987.
18 Singer CR, Linch DC: Comparison of the sensitivity of normal and
leukemic myeloid progenitors to in vitro incubation with cytotoxic
drugs: a study of pharmacological purging. Leuk Res 11:953, 1987.
19 Sindermann H, Peukert M, Hilgard P: Bone marrow purging with
mafosfamide—a critical survey. Blut 59:432, 1989.
20 Sphall EJ, Jones RB, Bast RC, Rosner G, Vandermark M, Ross M,
Affronti ML, Johnston C, Eggleston S, Terrperberg M, Coniglio D, Peters
WP: 4-Hydroperoxycyclophosphamide (4-HC) purging of breast can-
cer from the mononuclear cell fraction of bone marrow in patients
receiving high-dose chemotherapy and autologous marrow support: a
phase I trial. J Clin Oncol 9:85, 1990.
21 Kennedy MJ, Beveridge RA, Rowley S, Gordon GB, Abeloff MD,
Davidson NE: High-dose chemotherapy with reinfusion of purged
autologous bone marrow following dose-intense induction as initial
therapy for metastatic breast cancer. J Natl Cancer Inst 83:920, 1991. 
22 Rice A, Boiron J, Barbot C, Dupouy M, Dubsoc-Marchenay N, Dumain
P, Lacombe F, Reiffers J: Cytokine-mediated expansion of 5-FU resistant
peripheral blood stem cells and bone marrow: self-renewal and com-
mitment capacity. J Hematother 3:135, 1992.
23 Skala JP, Rogers PC, Chan KW, Rodriguez WC: Effect of ethiofos on
cytotoxicity of pharmacological purging protocols used for autologous
Table 2. Effects of culture conditions and 4-HC treatment on CFU and
nucleated cell output
Culture condition Fold increase Fold increase
and treatment in CFUa in TNCa
HS-5CM/KL –4-HC 47 Xb 460 X
+4-HC 98 Xc 4573 X
GFmix –4-HC 19 Xd 200 X
+4-HC 19 Xc 3549 X
aFold increase was calculated by dividing the total number of cells or CFU
produced by the number present before initiating the culture. Maximal pro-
ductions, which occurred at different times depending on culture conditions




BA Roecklein et al.
68
marrow grafts in acute lymphoblastic leukemia. Prog Clin Biol Res
377:57, 1992.
24 Brugger W, Scheding S, Vogel W, Kanz L: Purging of peripheral
blood progenitor cells. Ann Oncol 7:11, 1996.
25 Rowley SD, Piantodosi S, Marcellus D, Jones RJ, Davidson NE, Davis
JM, Kennedy J, Wiley JM, Wingard J, Yeager AM, Santos G: Analysis of
factors predicting speed of hematologic recovery after transplantation
with 4-hydroperoxycyclophosphamide-purged autologous marrow
grafts. Bone Marrow Transplant 7:183, 1991.
26 Rowley SD, Brasham-Stein C, Andrews R, and Bernstein ID: Hemato-
poietic precursors resistant to treatment with 4-hydroperoxycyclophos-
phamide: requirement for an interaction with marrow stroma in addi-
tion to hematopoietic growth factors for maximal generation of colony-
forming activity. Blood 82:60, 1993.
27 Bender JG, Williams SF, Myers S, Nottleman D, Lee WJ, Unverzagt
KL, Walker D, To LB, van Epps DE: Characterization of chemotherapy
mobilized peripheral blood progenitor cells for use in autologous stem
cell transplantation. Bone Marrow Transplant 10:281, 1992.
28 Bender JG, Lum L, Unverzagt KL, Lee W, van Epps D, George S,
Coon J, Ghalie R, McLeod B, Kaizer H, Williams SF: Correlation of
colony-forming cells, long-term culture initiating cells and CD34 cells
in apheresis products from patients mobilized for peripheral blood pro-
genitors with different regimens. Bone Marrow Transplant 13:479,
1994. 
29 van Epps DE, Bender J, Lee W, Schilling M, Smith A, Smith S,
Unverzagt K, Law P, Burgess J: Harvesting, characterization, and culture
of CD34 cells from human bone marrow, peripheral blood, and cord
blood. Blood Cells 20:411, 1994.
30 Steen R, Tjonnfjord GE, Egeland T: Comparison of the phenotype
and clonogenicity of normal CD34 cells from umbilical cord blood,
granulocyte colony-stimulating factor-mobilized peripheral blood, and
adult human bone marrow. J Hematother 3:253, 1994.
31 To LB, Haylock DN, Dowse T, Simmons PJ, Trimboli S, Ashman LK,
Juttner CA: A comparative study of the phenotype and proliferative
capacity of peripheral blood (PB) CD34 cells mobilized by four differ-
ent protocols and those of steady-phase PB and bone marrow CD34
cells. Blood 84:2930, 1994. 
32 Suzuki T, Muroi K, Tomizuka H, Amemiya Y, Miura Y: Characteri-
zation of enriched CD34 cells from healthy volunteers and those from
patients treated with chemotherapy plus granulocyte colony-stimulat-
ing factor (G-CSF). Stem Cells 13:273, 1995.
33 De Wynter EA, Coutinho LH, Pei X, Marsh JCW, Hows J, Luft T,
Testa NG: Comparison of purity and enrichment of CD34 cells from
bone marrow, umbilical cord and peripheral blood (primed for aphere-
sis) using ﬁve separation systems. Stem Cells 13:524, 1995. 
34 Ho AD, Young D, Maruyama M, Corringham RET, Mason JR,
Thompson P, Grenier K, Law P, Terstappen LWMM, Lane T: Pluripotent
and lineage-committed CD34 subsets in leukapheresis products mobi-
lized by G-CSF, GM-CSF vs. a combination of both. Exp Hematol
24:1460, 1996.
35 Prosper F, Stroncek D, Verfaillie CM: Phenotype and functional
characterization of long-term culture initiating cells present in periph-
eral blood progenitor collections of normal donors treated with granu-
locyte colony-stimulating factor. Blood 88:2033, 1996. 
36 Roecklein BA, Torok-Storb B: Functionally distinct human marrow
stromal cell lines immortalized by transduction with the human papillo-
mavirus E6/E7 genes. Blood 85:997, 1995.
37 Uchida N, Combs J, Chen S, Zanjani E, Hoffman R, Tsukamoto A:
Primitive human hematopoietic cells displaying differential efﬂux of the
rhodamine 123 dye have distinct biological activities. Blood 88:1297,
1996.
38 Gartner S, Kaplan HS: Long-term culture of human bone marrow
cultures. Proc Natl Acad Sci U S A 77:4756, 1980.
39 Eaves CJ, Cashman JD, Eaves AC: Methodology of long-term cul-
ture of human hematopoietic cells. J Cult Methods 13:55, 1991.
40 Taswell C: Limiting dilution assays for the determination of
immunocompetent cell frequencies. I. Data analysis. J Immunol
126:1614, 1981.
41 Sakabe H, Ohmizono Y, Tanimukai S, Kimura T, Mori K, Abe T, Son-
oda Y: Functional differences between subpopulations of mobilized
peripheral blood-derived CD34 cells expressing different levels of
HLA-DR, CD33, CD38 and c-kit antigens. Stem Cells 15:73, 1997.
42 Roecklein B, Torok-Storb B: Expansion of hematopoietic progenitors
and maintenance of LTCIC using serum-deprived medium conditioned
by the HS-5 stromal cell line. Blood 86:10, 1995. [abstr]
43 Uchida N, He D, Friera AM, Reitsman M, Sasaki D, Chen B,
Tsukamoto A: The unexpected G0/G1 cell cycle status of mobilized
hematopoietic stem cells from peripheral blood. Blood 89:465, 1997.
44 Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS,
Bearman SI, Peters WP, Bast RC Jr, McCulloch W, Capizzi R, Mitchell E,
Schein PS, Jones RB: Amifostine (WR-2721) shortens the engraftment
period of 4-hydroperoxycyclophosphamide-purged bone marrow in
breast cancer patients receiving high-dose chemotherapy with autolo-
gous bone marrow support. Blood 83:3132, 1994.
